Wells Fargo Starts Coverage of Sutro Biopharma with Aggressive $49 Price Target

Wells Fargo launched coverage of Sutro Biopharma with an overweight rating and $49 price target, representing over 200% upside from the stock's current $16.05 price. The biopharmaceutical company recently missed quarterly expectations, reporting an adjusted loss of $2.33 per share against the $2.19 estimate and revenue of $9.84 million below the $11.96 million consensus. Despite the recent earnings miss, analyst sentiment remains positive with consensus buy ratings and an average price target of $49.50.

Wells Fargo's initiation of coverage represents a significant show of confidence in Sutro Biopharma's future trajectory, despite the company's recent operational stumbles. The biopharmaceutical firm fell short on both earnings and revenue metrics in its latest quarter, with losses exceeding analyst expectations and sales coming in approximately 18% below projections. Nevertheless, the broad analyst community has coalesced around an optimistic outlook, with the vast majority recommending purchase at current valuations.

The stock's dramatic valuation gap—currently trading at roughly one-third of consensus price targets—suggests analysts believe Sutro's near-term earnings miss may not reflect longer-term commercial prospects. The company's market capitalization of $266 million positions it as a smaller-cap biotech play, where single-product approvals or trial outcomes could materially shift investor sentiment and fundamentals.